What one share of Tango Therapeutics holds
Tango Therapeutics was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We leverage our state-of-the-art target and drug discovery platforms to identify novel disease-relevant targets and develop medicines tailored to defined patient populations with high unmet medical need.
Tango Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.40 |
|---|---|
| Profit | −$0.92 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.07 |
| Cash and investments | $6.02 |
| Book value | $6.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.24 | −$1.63 | $0.03 | $2.16 | — | $0.96 |
| 2021 | $0.60 | −$0.94 | $0.03 | −$0.99 | — | $3.94 |
| 2022 | $0.28 | −$1.23 | $0.09 | −$1.33 | — | $2.83 |
| 2023 | $0.39 | −$1.08 | $0.02 | −$1.26 | — | $2.48 |
| 2024 | $0.39 | −$1.19 | $0.01 | −$1.21 | — | $1.85 |
| 2025 | $0.54 | −$0.87 | $0.01 | −$1.20 | — | $2.55 |
Common questions about Tango Therapeutics
How much does one share of Tango Therapeutics earn?
Over the last 12 months, Tango Therapeutics lost $0.92 for each share on $0.40 of sales.
Does Tango Therapeutics pay a dividend?
Tango Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Tango Therapeutics’s book value per share?
Tango Therapeutics’s book value is $6.08 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Tango Therapeutics have?
Each share of Tango Therapeutics has $6.02 of cash and investments, as of June 30, 2026.
What is Tango Therapeutics’s free cash flow per share?
−$1.07 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Tango Therapeutics bought back shares?
Tango Therapeutics’s share count rose about 264% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.